Evaluation of the histological and immunohistochemical subtype of breast cancer patients from a referral hospital in the inland of the state of São Paulo
DOI:
https://doi.org/10.29289/2594539420220019Palavras-chave:
breast neoplasms, immunohistochemistry, histologyResumo
ABSTRACT: Introduction: The immunohistochemical markers used in breast cancer cases allow the classification of tumors into four subtypes: luminal A (1), luminal B (2), HER2 positive (3), and triple-negative or basal-like (4). This study aimed to evaluate the histological and immunohistochemical profile of breast cancer patients from a referral hospital in the inland of the state of São Paulo and understand the particularities of the prognosis based on the tumor-node-metastasis staging. Methods: This retrospective observational epidemiological cohort study was carried out at Hospital Regional de Presidente Prudente, with the first half of 2020 as the time frame. The research target population was women diagnosed with breast cancer who underwent immunohistochemical examination. We excluded patients with breast carcinoma in situ and incomplete medical records, which made data analysis impossible. After classifying the cases into four molecular subtypes based on immunohistochemistry, identifying the histological grade, and verifying the pathological staging criteria, we gathered the data and addressed the pathological-prognostic staging to investigate the prognosis of each patient. Results: We analyzed 49 patients with a complete immunohistochemical profile. Among them, luminal A (44.9%) was the most prevalent molecular subtype, followed by luminal B (36.7%). The least prevalent subtypes were triple-negative (16.8%) and HER2 (2%). Pathological-prognostic staging was possible in 73.5% of cases. Conclusions: The molecular subtype is important for tumor evaluation and has direct implications for the staging of breast cancer patients.
Downloads
Referências
Instituto Nacional do Câncer (INCA). Conceito e Magnitude do câncer de mama. Rio de Janeiro: INCA; 2020.
Nazário, A. C. P. Mastologia: Condutas Atuais. 1st ed. Barueri: Manole; 2015.
Goske M, Ramachander VRV, Komaravalli PL, Rahman P, Rao C, Jahan P. CTLA-4 Genetic Variants (rs11571317 and rs3087243): role in susceptibility and progression of breast cancer. World J Oncol. 2017;8(5):162-70. https://doi.org/10.14740/wjon1046w
Sun T, Zhang W, Li Y, Jin Z, Du Y, Tian J, Xue H. Combination immunotherapy with cytotoxic T-lymphocyte-associated antigen-4 and Programmed death protein-1 inhibitors prevents postoperative breast tumor recurrence and metastasis. Mol Cancer Ther. 2020;19(3):802-11. https://doi.org/10.1158/1535-7163.MCT-19-0495
Cuzick J, Dowsett M, Pineda S, Wale C, Salter J, Quinn E, et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the genomic health recurrence score in early breast cancer. J Clin Onco. 2011;29(32):4273-8. https://doi.org/10.1200/JCO.2010.31.2835.
Yaghoobi V, Martinez-Morilla S, Liu Y, Charette L, Rimm D, Harigopal M. Advances in quantitative immunohistochemistry and their contribution to breast cancer. Expert Rev Mol Diagn. 2020;20(5):509-22. https://doi.org/10.1080/14737159.2020.1743178
Bonacho T, Rodrigues F, Liberal J. Immunohistochemistry for diagnosis and prognosis of breast cancer: a review. Biotech Histochem. 2020;95(2):71-91. https://doi.org/10.1080/10520295.2019.1651901.
Ellis MJ, Tao Y, Luo J, A’Hern R, Evans DB, Bhatnagar AS, et al. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst. 2008;100(19):1380-8. https://doi.org/10.1093/jnci/djn309.
Harris LN, Ismaila N, Mcshane LM, Andre F, Collyar DE, Gonzalez-Angulo AM, et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: american society of clinical oncology clinical practice guideline. J Clin Oncol. 2016;34(10):1134-50. https://doi.org/10.1200/JOP.2016.010868
Slamon JD, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177-82. https://doi.org/10.1126/science.3798106
Pandit P, Patil R, Palwe V, Gandhe S, Patil R, Nagarkar R. Prevalence of molecular subtypes of breast cancer: a single institutional experience of 2062 patients. Eur J Breast Health. 2020;16(1):39-43. https://doi.org/10.5152/ejbh.2019.4997
Azambuja E, Cardoso F, Castro G, Colozza M, Mano MS, Durbecq V. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12155 patients. Br J Cancer. 2007;96(10):1504-13. https://doi.org/10.1038/sj.bjc.6603756
Falck AK, Fernö M, Bendahl P, Rydén L. St Gallen molecular subtypes in primary breast cancer and matched lymph node metastases – aspects on distribution and prognosis for patients with luminal A tumours: results from a prospective randomised trial. Bmc Cancer. 2013;13(1):1-10. https://doi.org/10.1186/1471-2407-13-558
Gao JJ, Swain SM. Luminal a breast cancer and molecular assays: a review. The Oncologist; 2018;23(5):556-65. https://doi.org/10.1634/theoncologist.2017-0535
Al-Thoubaity FK. Molecular classification of breast cancer: a retrospective cohort study. Ann Med Surg (Lond). 2020;49:44-8. https://doi.org/10.1016/j.amsu.2019.11.021.
Ye DM, Li Q, Yu T, Wang HT, Luo YH, Li WQ. Clinical and epidemiologic factors associated with breast cancer and its subtypes among Northeast Chinese women. Cancer Med. 2019;8(17):7431-45. https://doi.org/10.1002/cam4.2589
Hortobagyi GH, Cannoly JL. AJCC Cancer Staging Manual. 8th ed. Chigago: Espringer; 2017.
Peruzzi CP, Andrade VRM. Análise dos marcadores imuno-histoquímicos associados com câncer de mama em mulheres na Região das Missões, Rio Grande do Sul, Brasil. Rev Bras Mastologia. 2016;26(4):181-5. https://doi.org/10.5327/Z201600040008RBM
Eroles P, Bosch A, Pérez-Fidalgo JA, Lluch A. Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. Cancer Treat Rev. 2012;38(6):698-707. https://doi.org/10.1016/j.ctrv.2011.11.005
Cirqueira MB, Moreira M, Soares LR, Cysneiros MA, Vilela MHT, Freitas-Junior R. Effect of Ki-67 on immunohistochemical classification of Luminal A to Luminal B subtypes of breast carcinoma. Breast J. 2015;21(5):465-72. https://doi.org/10.1111/tbj.12441
Cintra JRD, Teixeira MTB, Diniz RW, Gonçalves Junior H, Florentino TM, Freitas GF. Perfil imuno-histoquímico e variáveis clinicopatológicas no câncer de mama. Rev Assoc Med Bras. 2012;58(2):178-87. https://doi.org/10.1590/S0104-42302012000200013
Carvalho FM, Bacchi LM, Pincerato KM, Van de Rijn M, Bacchi CE. Geographic differences in the distribution of molecular subtypes of breast cancer in Brazil. BMC Womens Health. 2014;14:102. https://doi.org/10.1186/1472-6874-14-102
Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, et al. Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol. 2015;26(8):1533-46. https://doi.org/10.1093/annonc/mdv221
Harbeck N, Rastogi P, Martin M, Tolaney SM, Shao ZM, Fasching PA, et al. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. Ann Oncol. 2021;32(12):1571-81. https://doi.org/10.1016/j.annonc.2021.09.015
Horii R, Tsuda H, Masuda S, Sugita H, Togashi K, Ohno S, et al. Performance analysis of the anti-Ki67 antibody clone 30-9 for immunohistochemical staining of breast cancer. Breast Cancer. 2020;27(6):1058-64. https://doi.org/10.1007/s12282-020-01108-w
Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379(2):111-21. https://doi.org/10.1056/NEJMoa1804710
Cardoso F, Van't Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, et al. MINDACT investigators. 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med. 2016;375(8):717-29. https://doi.org/10.1056/NEJMoa1602253
Ribeiro CM, Correa FM, Migowsky. Efeitos de curto prazo da pandemia de COVID-19 na realização de procedimentos de rastreamento, investigação diagnóstica e tratamento do câncer no Brasil: estudo descritivo, 2019-2020. Epidemio Serv Saúde. 2022;31(1):e2021405. http://doi.org/10.1590/s1679-49742022000100010
Knutsvik G, Stefansson IM, Aziz S, Arnes J, Eide J, Collett K, et al. Evaluation of Ki67 expression across distinct categories of breast cancer specimens: a population-based study of matched surgical specimens, core needle biopsies and tissue microarrays. PLoS One. 2014;9(11):e112121. http://doi.org/10.1371/journal.pone.0112121
Eroles P, Bosch A, Pérez-Fidalgo JA, Lluch A. Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. Cancer Treat Rev. 2012;38(6):698-707. http://doi.org/10.1016/j.ctrv.2011.11.005.
Kang YJ, Baek JM, Kim YS, Jeon YW, Yoo TK, Rhu J, et al. Impact of the COVID-19 pandemic on the diagnosis and surgery of breast cancer: a multi-institutional study. J Breast Cancer. 2021;24(6):491-503. http://doi.org/10.4048/jbc.2021.24.e55
Tokunaga E, Ijichi H, Tajiri W, Masuda T, Takizawa K, Ueo H, et al. The comparison of the anatomic stage and pathological prognostic stage according to the AJCC 8th edition for the prognosis in Japanese breast cancer patients: data from a single institution. Breast Cancer. 2020;27(6):1137-46. http://doi.org/10.1007/s12282-020-01116-w
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2026 Isabela Costa da Silva, Gabrielle Aparecida Alves de Freitas, Thiago Rodrigues de Mello, Suelen Umbelino da Silva, Rafael da Silva Sá
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
